Genelux (GNLX) Projected to Post Quarterly Earnings on Monday

Genelux (NASDAQ:GNLX) is expected to post its results before the market opens on Monday, April 6th. Analysts expect Genelux to post earnings of ($0.22) per share for the quarter.

Genelux (NASDAQ:GNLX) last announced its earnings results on Thursday, March 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.01 million during the quarter. On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Price Performance

Shares of NASDAQ GNLX opened at $2.48 on Monday. Genelux has a 12 month low of $1.99 and a 12 month high of $8.53. The company has a market cap of $111.13 million, a price-to-earnings ratio of -2.88 and a beta of 0.15. The business has a fifty day simple moving average of $2.67 and a 200-day simple moving average of $4.12.

Wall Street Analysts Forecast Growth

GNLX has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating on shares of Genelux in a report on Monday, January 5th. Benchmark dropped their target price on shares of Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a research report on Friday, March 20th. Finally, Wall Street Zen upgraded shares of Genelux from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $20.40.

Insider Activity at Genelux

In other news, Director John Thomas sold 10,000 shares of Genelux stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $2.90, for a total transaction of $29,000.00. Following the transaction, the director owned 482,784 shares in the company, valued at approximately $1,400,073.60. The trade was a 2.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Genelux

Hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new stake in shares of Genelux during the 1st quarter valued at about $239,000. Jane Street Group LLC acquired a new position in Genelux in the first quarter worth approximately $190,000. Geode Capital Management LLC increased its holdings in Genelux by 1.8% in the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after buying an additional 5,596 shares during the last quarter. Marshall Wace LLP bought a new position in Genelux during the second quarter valued at approximately $92,000. Finally, Raymond James Financial Inc. raised its position in Genelux by 22.6% during the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after acquiring an additional 5,333 shares in the last quarter. 37.33% of the stock is owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.